Arcus Biosciences RCUS Other — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's other — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's other — total revenues?
- Arcus Biosciences (RCUS) reported other — total revenues of $2M in Q1 2026.
- What is the long-term trend for Arcus Biosciences's other — total revenues?
- Over 3 years (2022 to 2025), Arcus Biosciences's other — total revenues has grown at a -100.0% compound annual growth rate (CAGR), from $5M to $0.
- What does other — total revenues mean?
- This metric represents the total revenue generated from business activities or service offerings that fall outside the company's primary clinical-stage biopharmaceutical development pipeline. It captures income streams from ancillary operations, such as specialized research services or non-core licensing arrangements, which are not directly tied to the primary immuno-oncology product candidates. Monitoring this revenue helps investors assess the contribution of secondary business segments to the company's overall financial performance.